Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus

16 maggio 2026 aggiornato da: Yeu Kai Zhe, Mahsa University

Local Delivery of Lactobacillus Reuteri Probiotic as An Adjunct to Non-surgical Periodontal Therapy in Patients With Stage II, III, and IV Periodontitis and Type 2 Diabetes Mellitus: A Prospective Split-Mouth Clinical Trial

The purpose of the study is to evaluate the effectiveness of local delivery of Lactobacillus reuteri probiotic on periodontitis patients with type 2 diabetes mellitus, as an adjunct to non-surgical periodontal treatment. To date, the efficacy of local drug delivery as an adjunct has been established, whereas research on the effectiveness of probiotics as an adjunct remains limited. Specifically, there is a lack of studies focusing on the clinical effectiveness of Lactobacillus reuteri probiotic as an adjunct in subgingival debridement for patients with type 2 diabetes mellitus.

Over the past decade, there has been a growing interest in using probiotics to enhance periodontal health. Subsequent studies investigated the application of probiotics in individuals with periodontal disease, concluding that the depth of periodontal pockets in humans also decreases with probiotic use as part of periodontal treatment. Positive effects of probiotics have been reported at both the microbiological and immunological levels. Lactobacillus reuteri probiotic has also shown a notable decrease in pro-inflammatory markers and an increase in anti-inflammatory markers. Despite these findings, the clinical application of Lactobacillus reuteri probiotics in patients with type 2 diabetes mellitus has not yet been explored. Your participation will be about 6months duration.

If you agree to participate in the study, the doctor (YKZ) may need to perform some tests and examinations to determine if you are suitable for the study. If you are deemed suitable, you will be assigned to both of the treatment groups below (split-mouth study design). Both right (quadrant 1 and 4) and left (quadrant 2 and 3) halves will be assigned randomly to one of the two treatment modalities. The study products do not contain porcine, bovine or animal components.

  1. Oral hygiene instructions (OHI) + Professional mechanical plaque removal
  2. Root surface debridement (RSD)
  3. (a) Test group: L. reuteri probiotic subgingival applications on all pockets of ≥ 5mm

3. (b) Control group: Sterilised distilled water subgingival applications on all pockets of ≥ 5mm 4. The applications will be repeated again in both groups after initial applications on every 7, 14, 21 and 28 day.

Participating in this study, you will receive a complete set of oral hygiene kit. While participating, you may or may not experience direct benefits.

The risks for probiotic adjunctive non-surgical periodontal therapy, while generally considered safe, may pose some potential risk factors. Some potential risk factors may include:

  1. Temporary discomfort; Some individuals may experience temporary discomfort or pain following non-surgical periodontal procedures, such as scaling and root surface debridement. This discomfort typically subsides within a few days.
  2. Gingival and/ or root sensitivity; Some individuals may experience increased sensitivity in the gums or teeth, particularly to hot or cold temperatures, after non-surgical periodontal therapy.
  3. Bleeding gums; Individuals might notice temporary bleeding from the gums, especially during and immediately after the procedure. This is usually minor and resolves with proper post-operative care.
  4. Recession of gums; In rare instances, there may be a risk of gingival recession, where the gums pull away from the teeth. This is more likely in individuals with thin or fragile gum tissue.
  5. Infection; While rare, there is a potential risk of infection, particularly if proper hygiene practices are not followed after the procedure.
  6. Allergic reactions; Some individuals may be allergic to probiotic used during adjunctive non-surgical periodontal therapy, leading to allergic reactions (skin rashes or itchiness).

If you require additional information regarding risks and side effects, please consult your study doctor (YKZ). The trial staff will promptly update you on any new discoveries or modifications to the study product that may impact your health or willingness to continue in this study. If needed, you may be requested to provide your consent to participate again.

Nonetheless, the data and information collected will contribute to advancing the treatment or management of individuals with the same disease or condition.

Yes, you have the right to refuse to take part in the study at any time. You do not have to participate in this study to get treatment for your periodontal disease. Your participation in the research is entirely voluntary, and you can choose not to participate without any obligation or negative consequences.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

14

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Selangor
      • Hulu Langat, Selangor, Malaysia, 42610
        • Mahsa University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Individuals aged between 18 and 65 years;
  • Diagnosed with controlled type 2 diabetes mellitus (HbA1c < 7%);
  • Presence of a minimum of 20 natural teeth;
  • Untreated stage II, III, or IV periodontitis (Tonetti et al., 2018), with radiographic evidence of generalized alveolar bone loss;
  • At least one periodontal pocket per quadrant with a probing pocket depth of 5 mm and bleeding on probing.

Exclusion Criteria:

  • Participation in another clinical trial;
  • Pregnancy or lactation;
  • Smoker;
  • Individuals with autoimmune diseases;
  • Individuals with compromized medical conditions requiring prophylactic antibiotic therapy (e.g., patients with valvular prosthesis, patients with history of infective endocarditis, heart transplant recipients, etc.);
  • Individuals currently receiving ongoing drug therapy (corticosteroid, bisphosphonates, nonsteroidal anti-inflammatory drugs, etc.);
  • Use of systemic antibiotics within the 3 months prior to the study;
  • Use of probiotic products within the 3 months prior to the study;
  • History of subgingival instrumentation within the previous 6 months;
  • Presence of acute periodontal lesions and/or endo-periodontal lesions (Herrera et al., 2018);
  • Physical limitations that may interfere proper oral hygiene practices.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Probiotic Test group
Lactobacillus reuteri probiotic drops (a minimum of 100 colony forming units Lactobacillus reuteri DSM 17938 Protectis drops, BioGaia AB, Turnhout, Belgium) were administered subgingivally at the test sites
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.
Comparatore attivo: Distilled Water Control group
Sterile distilled water was administered subgingivally at the control sites
Applied with a syringe and blunt needle until overflowing from the periodontal pocket.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in the periodontal probing depth at 3 months and 6 months
Lasso di tempo: From enrollment to the end of treatment at 6 months
Probing pocket depth was measured as the distance from the free gingival margin (FGM) to the base of the periodontal pocket. All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe. Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
From enrollment to the end of treatment at 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in the plaque index at 3 months and 6 months
Lasso di tempo: From enrollment to the end of treatment at 6 months

Score 0 = No plaque in the gingival area. Score 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface.

Score 2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye.

Score 3 = Abundance of soft matter within the gingival pocket and/ or on the gingival margin and adjacent tooth surface.

From enrollment to the end of treatment at 6 months
Change from baseline in the gingival index at 3 months and 6 months
Lasso di tempo: From enrollment to the end of treatment at 6 months

Score 0 = Normal gingiva. Score 1 = Mild inflammation - slight change in color, slight oedema. No bleeding on probing.

Score 2 = Moderate inflammation - redness, oedema and glazing. Bleeding on probing.

Score 3 = Severe inflammation - marked redness and oedema. Ulceration. Tendency to spontaneous bleeding.

From enrollment to the end of treatment at 6 months
Change from baseline in the bleeding on probing at 3 months and 6 months
Lasso di tempo: From enrollment to the end of treatment at 6 months

Score 0 = Healthy looking papillary and marginal gingiva. No bleeding on probing.

Score 1 = Healthy looking gingiva. Bleeding on probing. Score 2 = Bleeding on probing. Change in color, no oedema. Score 3 = Bleeding on probing. Change in color, slight oedema. Score 4 = Bleeding on probing. Change in color, obvious oedema. Score 5 = Spontaneous bleeding. Change in color, marked oedema.

From enrollment to the end of treatment at 6 months
Change from baseline in the clinical attachment level at 3 months and 6 months
Lasso di tempo: From enrollment to the end of treatment at 6 months
Clinical attachment level was measured as the distance from the cemento-enamel junction (CEJ) of the tooth to the base of the periodontal pocket. All measurements were recorded to the nearest millimeter using a standardized and graduated UNC-15 periodontal probe. Six sites per tooth were examined, namely mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual.
From enrollment to the end of treatment at 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 luglio 2024

Completamento primario (Effettivo)

31 dicembre 2025

Completamento dello studio (Effettivo)

31 dicembre 2025

Date di iscrizione allo studio

Primo inviato

15 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 maggio 2026

Primo Inserito (Effettivo)

20 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 maggio 2026

Ultimo verificato

1 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Lactobacillus reuteri DSM 17938

Sottoscrivi